Deerfield Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Deerfield Management’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-250,000	Closed	-$2.99M	–	126
2022 Q3	$2.99M	Hold	250,000	–	–	0.06%	102
2022 Q2	$3.15M	Sell	250,000 -735,568	-75%	-$6.85M	0.07%	100
2022 Q1	$11.1M	Hold	985,568	–	–	0.25%	68
2021 Q4	$17.5M	Sell	985,568 -42,940	-4%	-$906K	0.37%	62
2021 Q3	$23.7M	Buy	1,028,508 +8,508	+0.8%	+$185K	0.46%	62
2021 Q2	$23.7M	Buy	1,020,000 +675,000	+196%	+$17.2M	0.42%	77
2021 Q1	$10.8M	Hold	345,000	–	–	0.23%	97
2020 Q4	$13.7M	Buy	+345,000	New	+$13.8M	0.27%	92

Other funds holding KNTE

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Deerfield Management's KNTE Position: Q4 2022 in Review

Deerfield Management sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2022, closing a stake of 250,000 shares — an estimated $2.99M sold.

Deerfield Management first reported a position in KNTE in Q4 2020 and held it in 8 quarters. The position peaked at $23.7M in Q2 2021. 79 funds tracked by Wall St. Rank hold KNTE as of Q4 2022.

Deerfield Management reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Deerfield Management sold 250,000 Kinnate Biopharma Inc. Common Stock shares in Q4 2022, an estimated $2.99M.
Deerfield Management first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 8 quarters.
Deerfield Management's Kinnate Biopharma Inc. Common Stock position peaked at $23.7M in Q2 2021.
79 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2022.

Based on Deerfield Management's 13F filing for Q4 2022, filed 14 Feb 2023.